Collectively, our results demonstrate that the combination of targeting the PI3K pathway through inhibition of PI3Kβ or AKT and activating the pro-apoptotic pathway through inhibition of Mcl-1 is able to deliver greater anti-tumour benefit in vivo at tolerable doses in PTEN-deficient breast tumors. Here, MCL1 is linked to breast neoplasm.